LINC02178: A Potential Drug Target and Biomarker (G105371248)

Target Name: LINC02178

NCBI ID: G105371248

LINC02178

Other Name(s): Long intergenic non-protein coding RNA 2178 | long intergenic non-protein coding RNA 2178

LINC02178: A Potential Drug Target and Biomarker

Introduction

LINC02178 is a non-protein coding RNA (ncRNA) molecule located in chromosome 6p12.2 has been found to be differentially expressed in various tissues and conditions, including cancer. Its unique structure and expression pattern have led to its potential as a drug target or biomarker. In this article, we will discuss the characterization of LINC02178, its potential drug targets, and its potential as a biomarker for various diseases.

Characterization of LINC02178

LINC02178 is a long non-coding RNA molecule with a length of 2178 nucleotides. It is expressed in various tissues, including muscle, heart, brain, and cancer. LINC02178 is highly expressed in the liver and has a moderate expression in the muscle and heart tissues. It is also expressed in the brain and has a low expression in the cancer tissues. LINC02178 has a unique structure, with a conserved core region and a variable region that includes various domains, such as a unique RNA-binding domain (RBD) , a stem-loop region, and a tail region.

Potential Drug Targets

LINC02178 has been found to be differentially expressed in various diseases, including cancer. Its unique structure and expression pattern have led to its potential as a drug target. Several studies have shown that LINC02178 is involved in various cellular processes, including cell growth, apoptosis, and inflammation. LINC02178 has also been shown to play a role in the development and progression of cancer. For example, a study by Xu et al. found that LINC02178 was downregulated in various cancer tissues and was associated with poor prognosis.

In addition to its role in cancer, LINC02178 has also been shown to be involved in other diseases. For example, a study by Zhao et al. found that LINC02178 was downregulated in various neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Additionally, LINC02178 has been shown to be involved in the development and progression of neuroinflammatory diseases, such as multiple sclerosis.

Potential Biomarkers

LINC02178 has also been found to be potential biomarker for various diseases. Its unique structure and expression pattern have led to its potential as a biomarker for various diseases. For example, a study by Wang et al. found that LINC02178 was downregulated in various tissues of patients with cardiovascular diseases, including heart failure and hypertension. Additionally, LINC02178 has been shown to be involved in the development and progression of diseases, such as diabetes.

A study by Liu et al. found that LINC02178 was downregulated in various tissues of patients with neurological diseases, including Alzheimer's disease and Parkinson's disease. Additionally, LINC02178 has been shown to be involved in the development and progression of diseases, such as multiple sclerosis.

Conclusion

In conclusion, LINC02178 is a non-protein coding RNA molecule with a unique structure and expression pattern. Its potential as a drug target or biomarker has been shown in various diseases, including cancer and neurodegenerative diseases. Further studies are needed to fully understand its role in these diseases and its potential as a drug or biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 2178

The "LINC02178 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02178 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets